FibroGen (NASDAQ:FGEN) Now Covered by Analysts at StockNews.com

StockNews.com began coverage on shares of FibroGen (NASDAQ:FGEN) in a research report released on Wednesday. The firm issued a hold rating on the biopharmaceutical company’s stock.

Several other research analysts have also issued reports on FGEN. William Blair reaffirmed a “market perform” rating on shares of FibroGen in a research note on Wednesday, November 13th. HC Wainwright raised FibroGen to a “strong-buy” rating in a research note on Tuesday, December 17th.

FibroGen Stock Performance

NASDAQ FGEN opened at $0.53 on Wednesday. The firm has a 50-day simple moving average of $0.38 and a 200 day simple moving average of $0.53. FibroGen has a twelve month low of $0.18 and a twelve month high of $2.93. The stock has a market cap of $53.36 million, a PE ratio of -0.43 and a beta of 0.82.

FibroGen (NASDAQ:FGEN) last issued its earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.17) EPS for the quarter, beating the consensus estimate of ($0.38) by $0.21. The firm had revenue of $46.33 million during the quarter, compared to analyst estimates of $34.00 million. During the same quarter in the prior year, the firm posted ($0.52) EPS. Research analysts forecast that FibroGen will post -0.86 earnings per share for the current fiscal year.

Hedge Funds Weigh In On FibroGen

Several large investors have recently modified their holdings of the stock. Point72 DIFC Ltd boosted its stake in shares of FibroGen by 734.2% in the second quarter. Point72 DIFC Ltd now owns 52,254 shares of the biopharmaceutical company’s stock valued at $47,000 after buying an additional 45,990 shares during the period. Doheny Asset Management CA acquired a new stake in shares of FibroGen during the 2nd quarter worth approximately $48,000. Point72 Asia Singapore Pte. Ltd. acquired a new position in FibroGen during the second quarter valued at approximately $130,000. Sei Investments Co. boosted its holdings in shares of FibroGen by 38.4% in the 2nd quarter. Sei Investments Co. now owns 149,342 shares of the biopharmaceutical company’s stock valued at $133,000 after purchasing an additional 41,442 shares in the last quarter. Finally, Squarepoint Ops LLC acquired a new stake in FibroGen in the second quarter valued at about $145,000. 72.71% of the stock is owned by institutional investors.

FibroGen Company Profile

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.